These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8785982)

  • 1. A non-lethal bioassay for potency testing of therapeutic clostridial neurotoxins.
    Sesardic D; Ekong T; McLellan KH; Das RG
    Dev Biol Stand; 1996; 86():342. PubMed ID: 8785982
    [No Abstract]   [Full Text] [Related]  

  • 2. Alternatives in testing of bacterial toxins and antitoxins.
    Sesardic D
    Dev Biol (Basel); 2002; 111():101-8. PubMed ID: 12678229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of an in vitro endopeptidase assay for detection of residual toxin activity in tetanus toxoids.
    Leung T; Corran PH; Gee C; Ekong TA; Sesardic D
    Dev Biol (Basel); 2002; 111():327-32. PubMed ID: 12678257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunoenzimatic detection of the Clostridium tetani bacterial toxin: an alternative to mice bioassays].
    Chaves F; León G; Hernández-Chavarría F
    Rev Biol Trop; 2006 Jun; 54(2):253-6. PubMed ID: 18494295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steps towards the development of a replacement in vitro test for quantification of antibodies to tetanus toxin during potency testing of vaccine.
    Southern J; Clements H; Spenceley L
    Dev Biol Stand; 1996; 86():343. PubMed ID: 8785983
    [No Abstract]   [Full Text] [Related]  

  • 6. Requirements for valid alternative assays for testing of biological therapeutic agents.
    Sesardic D
    Dev Biol Stand; 1996; 86():311-8. PubMed ID: 8785962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental conditions substantially influence botulinum toxin potency testing.
    Mander G; Fink K; Vey M
    Clin Neuropharmacol; 2009; 32(4):234; author reply 235. PubMed ID: 19644233
    [No Abstract]   [Full Text] [Related]  

  • 8. The development of non-animal-based bioassays for cytokines and growth factors.
    Mire-Sluis AR
    Dev Biol Stand; 1999; 101():169-75. PubMed ID: 10566790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in animal use in the production and testing of biologicals.
    Festing MF
    Dev Biol Stand; 1999; 101():195-200. PubMed ID: 10566793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation and validation of a single-dilution potency assay based upon serology of vaccines containing diphtheria toxoid: analysis for consistency in production and testing.
    Akkermans AM; Hendriksen CF; Marsman FR; van de Donk HJ
    Dev Biol Stand; 1996; 86():323-4. PubMed ID: 8785964
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro physiological studies on clostridial neurotoxins. Biological models and procedures for extracellular and intracellular application of toxins.
    Poulain B; Bader MF; Molgó J
    Methods Mol Biol; 2000; 145():259-86. PubMed ID: 10820727
    [No Abstract]   [Full Text] [Related]  

  • 12. Is the mouse weight gain test outdated as a model for the assessment of pertussis toxicity?
    Straaten-van der Kappelle IV; van der Gun J; van der Ark A; Hendriksen C
    Dev Biol Stand; 1996; 86():344. PubMed ID: 8785984
    [No Abstract]   [Full Text] [Related]  

  • 13. Developments in reduction and replacement of in vivo toxicity and potency tests for pertussis vaccines.
    Xing D; Canthaboo C; Douglas-Bardsley A; Yuen CT; Prior S; Liu Y; Corbel M
    Dev Biol (Basel); 2002; 111():57-68. PubMed ID: 12678225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the enzymatic activity of tetanus toxin.
    Montecucco C
    Toxicon; 1987; 25(12):1255-63. PubMed ID: 3438917
    [No Abstract]   [Full Text] [Related]  

  • 15. Alternative approach and evaluation of three potency assay methods for testing adsorbed tetanus toxoid.
    Maheshwari SC; Sharma SB; Kumar A; Sokhey J
    J Commun Dis; 1998 Mar; 30(1):12-8. PubMed ID: 9842159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormones: the role of the European Pharmacopoeia.
    Charton E
    Dev Biol Stand; 1999; 101():159-67. PubMed ID: 10566789
    [No Abstract]   [Full Text] [Related]  

  • 17. Quality control for screening-assays by means of control charts: polio vaccine testing as an example.
    Vogel I
    Dev Biol Stand; 1996; 86():346. PubMed ID: 8785986
    [No Abstract]   [Full Text] [Related]  

  • 18. The botulinum toxin LD50 potency assay - another chapter, another mystery.
    Pickett A
    Altern Lab Anim; 2012 Sep; 40(4):221-3. PubMed ID: 23067303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoption of three Rs alternatives for regulatory testing of vaccines in the developing world: possibilities and barriers.
    Di Fabio JL; Jaramillo MT; Arciniega JL
    Dev Biol (Basel); 2002; 111():195-8. PubMed ID: 12678241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological assays as alternatives to the Ph Eur challenge test for batch release of tetanus vaccines for human use.
    Winsnes R; Hendriksen C; Sesardic D; Akkermans A; Daas A
    Dev Biol Stand; 1999; 101():277-88. PubMed ID: 10566802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.